Almac said that the service – which is part of its biomarker discovery and development business – enables additional profiling of patient samples for pharma customers whose samples are currently analysed using bespoke assays.
The Illumina panel was developed to allow targeted DNA sequencing and reporting on the mutation status of 26 genes which are most commonly mutated in solid tumors including lung, colon, ovarian, melanoma and gastric cancers.
Paul Harkin, president of Almac’s Diagnostic business, said: “Almac is committed to the development of personalised medicine through the delivery of a wide range of innovative solutions. We are pleased to announce the expansion of our NGS service.”